Author

A.-L. Levonen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

I. Selvarajan· 2 shared J. Harkonen· 2 shared M. U. Kaikkonen· 2 shared S. Adinolfi· 2 shared A. Hemmes· 1 shared A. J. Deen· 1 shared A. Jawahar-Deen· 1 shared A. Knuuttila· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Selvarajan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells

A. J. Deen, S. Adinolfi, J. Harkonen, T. Patinen, X. Liu, T. Laitinen, P. Takabe, K. Kainulainen, S. Pasonen-Seppanen, L. Gawriyski, U. Thanigai Arasu, I. Selvarajan, P. Makinen, H. Laitinen, E. Kansanen, , A.-L. Levonen

This study shows that KEAP1 mutations in lung cancer activate TRAF2-NFκB signaling, enhancing cell survival by preventing apoptosis.

bioRxiv · Oct 10, 2023Cancer Biology

Pan-cancer scale screening reveals NRF2 associated immunoevasive characteristics in non-small cell lung cancer and squamous malignancies

J. Harkonen, P. Polonen, A. Jawahar-Deen, I. Selvarajan, H.-R. Teppo, E. Dimova, T. Kietzmann, M. Ahtiainen, T. Eklund, T. Kuopio, E.-M. Talvitie, P. Taimen, M. Kallajoki, M. U. Kaikkonen, M. Heinaniemi, A.-L. Levonen

This paper identifies NRF2-associated immunoevasive features in NSCLC and squamous cancers, linking NRF2 activity to immune-cold phenotypes and potential biomarkers for immune checkpoint response.

bioRxiv · May 15, 2022 · PreprintCancer Biology

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer

K. Wennerberg, E. W. Verschuren, S. Talwelkar, M. I. Mäyränpää, J. Schüler, N. Linnavirta, A. Hemmes, S. Adinolfi, M. Kankainen, W. Sommergruber, A.-L. Levonen, J. Räsänen, A. Knuuttila

The paper identifies PI3Kβ as a mediator of resistance to ALK inhibitors in ALK-rearranged lung cancer and shows that combining ALK and PI3Kβ inhibitors overcomes resistance.

bioRxiv · Mar 18, 2021 · PreprintCancer Biology